Agios Pharmaceuticals Inc.'s AG-881 showed a favorable safety profile in certain patients with solid tumors.
In an ongoing phase 1 trial, the company is evaluating the safety and tolerability of AG-881 in patients with advanced solid tumors, including glioma, with mutations in the IDH1 or IDH2 genes. A glioma is a type of tumor that starts in the glial cells of the brain or the spine.
As of March 29, 93 patients have been treated with the drug, with the safety analysis conducted for all these patients showing that AG-881 has a favorable safety profile at dose levels below 100 mg.
Out of 52 glioma patients in the trial, 75% did not see an increase or decrease in the severity of their disease. One patient had a sustained minor response and remains on treatment.
Among the 41 patients with non-glioma solid tumors, 37% did not see their disease increase or decrease in severity and 44% saw a progression in their tumors.
The majority of the side effects reported in the trial were mild to moderate, with the most common being fatigue, nausea as well as increases in levels of certain enzymes.
The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.
